Precision BioSciences, Inc.
NASDAQ: DTIL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Juli Blanche
- Employees
- 108
- Headquarters
- Durham, United States
- IPO year
- 2019
- Market cap
- $86.5M
- Website
- https://www.precisionbiosciences.com
Loading DTIL…
Loading profile data…Frequently asked questions about DTIL
What does Precision BioSciences, Inc. (DTIL) do?
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfo...
Where does DTIL trade?
Precision BioSciences, Inc. (DTIL) trades on the NASDAQ Global Select.
What sector is DTIL in?
Precision BioSciences, Inc. (DTIL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Precision BioSciences, Inc.?
Juli Blanche is the chief executive officer of Precision BioSciences, Inc. (DTIL).
Where is Precision BioSciences, Inc. headquartered?
Precision BioSciences, Inc. is headquartered in United States.
Does DTIL pay a dividend?
Precision BioSciences, Inc. (DTIL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DTIL go public?
Precision BioSciences, Inc. (DTIL) completed its initial public offering in 2019.